Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.

Cancer
Bradley Alexander McGregorToni K Choueiri

Abstract

In this multicenter, single-arm, multicohort, phase 2 trial, the efficacy of nivolumab and ipilimumab was evaluated in patients with advanced rare genitourinary cancers, including bladder and upper tract carcinoma of variant histology (BUTCVH), adrenal tumors, platinum-refractory germ cell tumors, penile carcinoma, and prostate cancer of variant histology (NCT03333616). Patients with rare genitourinary malignancies and no prior immune checkpoint inhibitor exposure were enrolled. Patients received nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg intravenously every 3 weeks for 4 doses, and this was followed by 480 mg of nivolumab intravenously every 4 weeks. The primary endpoint was the objective response rate (ORR) by the Response Evaluation Criteria in Solid Tumors (version 1.1). Fifty-five patients were enrolled at 6 institutions between April 2018 and July 2019 in 3 cohorts: BUTCVH (n = 19), adrenal tumors (n = 18), and other tumors (n = 18). The median follow-up was 9.9 months (range, 1 to 21 months). Twenty-eight patients (51%) received 4 doses of nivolumab and ipilimumab; 25 patients received nivolumab maintenance for a median of 4 cycles (range, 1-18 cycles). The ORR for the entire study was 16% (80% confidence interval, 1...Continue Reading

Associated Clinical Trials

References

Mar 23, 2006·The Journal of Clinical Endocrinology and Metabolism·Bruno Allolio, Martin Fassnacht
Jul 27, 2007·The New England Journal of Medicine·Lawrence H EinhornRafat Abonour
May 6, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arlene O Siefker-RadtkeRandall E Millikan
May 4, 2012·The New England Journal of Medicine·Martin FassnachtUNKNOWN FIRM-ACT Study Group
Jan 8, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G SonpavdeG Di Lorenzo
Jan 16, 2014·Endocrine Reviews·Tobias ElseGary D Hammer
Jun 25, 2014·Critical Reviews in Oncology/hematology·André P FayToni K Choueiri
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
Feb 18, 2017·The New England Journal of Medicine·Joaquim BellmuntUNKNOWN KEYNOTE-045 Investigators
Oct 19, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N AdraN H Hanna
Mar 22, 2018·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 214 Investigators
Mar 22, 2018·Immunity·Chong SunTon N Schumacher
Sep 1, 2018·Nature Reviews. Urology·Bradley McGregor, Guru Sonpavde
Oct 4, 2018·The New England Journal of Medicine·Leora HornUNKNOWN IMpower133 Study Group
Feb 20, 2019·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
Mar 27, 2019·European Urology Focus·Bradley A McGregor, Guru P Sonpavde
May 18, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Padmanee SharmaJonathan Rosenberg
Sep 20, 2019·Journal for Immunotherapy of Cancer·Mouhammed Amir HabraAung Naing
Oct 21, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Neal E ReadyDavid R Spigel
Oct 24, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nitya RajDiane L Reidy-Lagunes
Nov 28, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emmanuel S AntonarakisJohann Sebastian de Bono
Jan 9, 2020·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 24, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sandip P PatelRazelle Kurzrock
Mar 20, 2020·Journal for Immunotherapy of Cancer·Aung NaingMouhammed Amir Habra

❮ Previous
Next ❯

Citations

Jan 13, 2021·Nature Reviews. Urology·Jeanny B Aragon-Ching
Jul 15, 2021·Future Science OA·Carlo BuonerbaGiuseppe Di Lorenzo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.